The HHS National Alzheimer's Plan Update for 2026-2035 keeps Medicare coverage for approved amyloid drugs while pushing prevention, better care, and family support. For adult children, the practical questions are what Medicare pays, what it costs, and where to get help.
The National Plan is the federal strategy for Alzheimer's disease and related dementias. HHS released the 2026 Update on Oct. 22, 2026, replacing six prior goals with four focused on risk reduction, research innovation, high-value care, and family supports.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What changed in the 2026 update?
- Does Medicare cover Leqembi and Kisunla, and at what cost?
- Why is access still difficult?
- What caregiver support can you use now?
What changed in the 2026 update?
The update narrows federal work to four goals: reduce risk, speed research, deliver high-value care, and support families. HHS says the shift is meant to focus action on prevention and caregiving, as described in the HHS announcement. Congress extended the law behind the plan through 2035. The NAPA Reauthorization Act, signed Oct.
1, 2024, requires continued annual federal updates, according to Rep. Paul Tonko and HHS summaries. For families, the change means planning around two tracks at once. Medical options remain limited and selective, while caregiver programs and prevention research get more attention.
Does Medicare cover Leqembi and Kisunla, and at what cost?
CMS covers the FDA traditionally approved amyloid antibodies Leqembi and Kisunla under Medicare Part B with evidence development. Coverage requires Medicare enrollment, mild cognitive impairment or mild dementia, documented amyloid pathology, and clinician registry submission.
Families face 20 percent Part B coinsurance for Leqembi under Original Medicare after the deductible, with the amount varying by Medigap or Medicare Advantage. List prices are around 26,500 dollars yearly for Leqembi and 32,000 dollars yearly for Kisunla, according to CMS in the broader Medicare coverage statement. Ask the clinic for a written check before starting:.
- Does the diagnosis meet the mild-stage requirement
- Is amyloid testing documented and accepted
- Will the prescribing clinician submit registry data
- What is the expected coinsurance under the parent's plan
Why is access still difficult?
Coverage has not produced wide use. CMS told STAT in May 2026 that it foresaw no significant Medicare spending on Leqembi and Kisunla in 2026-2027, down sharply from earlier multibillion-dollar projections, as reported in the STAT spending report. That gap points to barriers beyond the coverage rule.
Eligible patients need specialty evaluation, amyloid confirmation, infusion access, and monitoring for side effects. Travel time, caregiver leave, and out-of-pocket costs can stop treatment even when Medicare would pay its share. Adult children can narrow the search fast. Call the memory clinic, infusion site, and plan together, then compare referral wait, testing steps, visit frequency, and total yearly cost.
What caregiver support can you use now?
The CMS GUIDE Model offers dementia care navigation through participating Medicare organizations. The 8-year voluntary model launched July 1, 2024 with 390 organizations, according to CMS in the GUIDE fact sheet. Participants can receive a care navigator, round-the-clock access to support, caregiver education, and respite care.
The stated aim is to help people with dementia remain at home longer. Check whether a parent's doctor or health system takes part in GUIDE. If not, ask for social work, dementia care management, or local respite options that provide similar navigation and relief.
You Might Also Like
- The $100 Million PROTECT-Cog Alzheimer’s Study Announced in 2026: Questions People With Mild Cognitive Impairment Can Ask About the Research
- Day-One Subcutaneous Leqembi for Early Alzheimer’s in 2026: Safety and Monitoring Questions for Anti-Amyloid Treatment Patients
- How 2026 Tau Imaging News May Affect Alzheimer’s Workups: Accuracy, Limits, and Evidence Gaps for Younger-Onset Alzheimer’s Families
